Genetically, MLS belongs to a group of more than ten different sarcoma entities all defined by FET (FUS, EWSR1 and TAF15) fusion oncogenes, which are formed by the N-terminal part of FET genes fused to one of various transcription factor partners [2, 3]. The gene discussed is FUS; the disease is McLeod neuroacanthocytosis syndrome.